Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD) a clinical-stage biopharmaceutical company focused on the development of CART-cell therapies,  today announced that the company will present recent advances in Celyad’s pipeline at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting being held May 16–19, 2018, in Chicago.

Poster presentations will highlight the recent developments of Celyad’s pipeline in autologous and allogeneic platforms to address cancers. The oral presentation will give updated data of the ongoing THINK Phase 1 trial with the case report of a CYAD-01 associated complete response in one relapsed/refractory AML patient, including observations concerning the modulation of systemic chemokines during the course of treatment.

David Gilham, VP of Research and Development at Celyad, commented: Our presentations at the 2018 meeting of the ASGCT will share our increasing knowledge around our lead NKG2D CAR T cell candidate along with discussing our pipeline including the B7H6 CAR T program and our allogeneic platform. These presentations are the culmination of an intensive level of activity within our R&D group. We anticipate that this will lead to a series of assets that will enter clinical stage testing during 2019.’

 

Presentation Details:

Title

Early Signs of Clinical Activity in AML Patients Receiving NKG2D CAR-T Cell Therapy in the Absence of Pre-Conditioning Chemotherapy: An Alternative Strategy to CAR-T Cell Therapy

Link

Number

967

Category

Cancer-Immunotherapy, Cancer Vaccines

Session

412 Advancements in T Cell-Based Therapies

Session Date & Time

Saturday, May 19, 2018, 11:00 AM CDT

Location

Continental Ballroom ABC

 

Posters Details:

Poster title

Functional screening of a B7H6 specific chimeric antigen receptor (CAR)

Link

Poster Number

123

Category

Cancer - Immunotherapy, Cancer Vaccines I      

Session

Exhibit Hall Welcome Reception & Poster Session I

Session Date & Time

Wednesday, May 16, 2018, 5:30 PM CDT

Location

Stevens Salon C, D

 

 

Poster Title

Overcoming target-driven fratricide for CAR-T cell therapy

Link

Poster Number

119

Category

Cancer-Immunotherapy, Cancer Vaccines

Session

Exhibit Hall Welcome Reception & Poster Session I

Session Date & Time

Wednesday, May 16, 2018, 5:30 PM CDT

Location

Stevens Salon C, D

 

 

Poster Title

Expression of a TIM8 peptide reduces alloreactivity of T cells facilitating an allogeneic NKG2D Chimeric Antigen Receptor T cell therapy approach

Link

Poster Number

457

Category

Cell Therapies  

Session

Exhibit Hall Networking Reception & Poster Session II

Session Date & Time

Thursday, May 17, 2018, 5:15 PM CDT

Location

Stevens Salon C, D

 

                            

Download press release(s)

Press release

264.91 Ko

Communiqué de presse

273.13 Ko

Persbericht

263.38 Ko

Celyad Announces First Quarter 2018 Business Update

Next News

Celyad Announces First Quarter 2018 Business Update